The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“There is also evidence from studies performed both in vitro and in vivo of metformin’s role in attenuating tumorigenesis (Anisimov and Bartke, 2013; Karnevi et al., 2013; Liu et al., 2011; Quinn et al., 2013; Salani et al., 2012; Tosca et al., 2010).”
From Metformin as a tool to target aging (2016) · cites this paper as Liu et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
Calle, E. E., & Kaaks, R. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1408 · Cited by 3,613
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression
Shackelford, D. B., & Shaw, R. J. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2676 · Cited by 1,943
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880 · cited 1×
“001).(20) Randomized, prospective trials of metformin treatment, with or without other drugs are actively enrolling patients.”
BackgroundTargeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873
Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes
Landman, G. W. D., Kleefstra, N., van Hateren, K. J. J., Groenier, K. H., Gans, R. O. B., & Bilo, H. J. G. (2010) · Diabetes Care · doi:10.2337/dc09-1380 · Cited by 502
Flagged first, then by citations
Research works printed but not linked: 37
- Nahta R, Esteva FJ. Trastuzumab: triumphs and tribula- tions. Oncogene 2007; 26:3637-43; PMID:17530017; DOI:10.1038/sj.onc.1210379. · DOI
- Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357:39-51; PMID:17611206; DOI:10.1056/NEJMra043186. · DOI
- Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92; PMID:11248153; DOI:10.1056/ NEJM200103153441101. · DOI · Paper page
- Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treat- ment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719-26; PMID:11821453; DOI:10.1200/JCO.20.3.719. · DOI · Paper page
- Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007; 18:977-84; PMID:17229773; DOI:10.1093/ annonc/mdl475. · DOI
- Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metfromin and reduced risk of cancer in diabetic patients. BMJ 2005; 330:1304-5; PMID:15849206; DOI:10.1136/ bmj.38415.708634.F7. · DOI · Paper page
- Martin-Castillo B, Dorca J, Vazquez-Martin A, Oliveras-Ferraros C, Lopez-Bonet E, Garcia M, et al. Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo- adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology. Ann Oncol 2010; 21:187-9; PMID:19884247; DOI:10.1093/annonc/mdp494. · DOI
- Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian tar- get of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67:10804-12; PMID:18006825; DOI:10.1158/0008-5472.CAN- 07-2310. · DOI · Paper page
- Kalender A, Selvaraj A, Kim SY, Gulati P, Brule S, Viollet B, et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent man- ner. Cell Metab 2010; 11:390-401; PMID:20444419; DOI:10.1016/j.cmet.2010.03.014. · DOI · Paper page
- Mitra D, Brumlik MJ, Okamgba SU, Zhu Y, Duplessis TT, Parvani JG, et al. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol Cancer Ther 2009; 8:2152-62; PMID:19671734; DOI:10.1158/1535- 7163.MCT-09-0295. · DOI
- Nahta R, Esteva FJ. HER2 therapy: molecular mecha- nisms of trastuzumab resistance. Breast Cancer Res 2006; 8:215; PMID:17096862; DOI:10.1186/ bcr1612. · DOI
- Kumar R. ErbB-dependent signaling as a determinant of trastuzumab resistance. Clin Cancer Res 2007; 13:4657-9; PMID:17699840; DOI:10.1158/1078- 0432.CCR-07-1401. · DOI
- Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006; 3:269-80; PMID:16683005; DOI:10.1038/ncponc0509. · DOI
- Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E. Metformin disrupts crosstalk between G protein-cou- pled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 2009; 69:6539-45; PMID:19679549; DOI:10.1158/0008- 5472.CAN-09-0418. · DOI
- Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, et al. A central role for HER3 in HER2- amplified breast cancer: implications for targeted ther- apy. Cancer Res 2008; 68:5878-87; PMID:18632642; DOI:10.1158/0008-5472.CAN-08-0380. · DOI
- Wang S, Huang X, Lee CK, Liu B. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overex- pressing breast cancer cells via upregulation of Survivin. Oncogene 2010; 29:4225-36; PMID:20498641; DOI:10.1038/onc.2010.180. · DOI
- Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contrib- utes to trastuzumab resistance of breast cancer cells. Cancer Res 2005; 65:11118-28; PMID:16322262; DOI:10.1158/0008-5472.CAN-04-3841. · DOI · Paper page
- Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB recep- tor network. Clin Cancer Res 2007; 13:4909-19; PMID:17699871; DOI:10.1158/1078-0432.CCR-07- 0701. · DOI · Paper page
- Dann SG, Selvaraj A, Thomas G. mTOR Complex1-S6K1 signaling: at the crossroads of obe- sity, diabetes and cancer. Trends Mol Med 2007; 13:252-9; PMID:17452018; DOI:10.1016/j.mol- med.2007.04.002. · DOI
- Luo Z, Zang M, Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol 2010; 6:457-70; PMID:20222801; DOI:10.2217/fon.09.174. · DOI
- Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Metformin and cancer: Doses, mechanisms and the dandelion and hormetic phenom- ena. Cell Cycle 2010; 9:1057-64; PMID:20305377; DOI:10.4161/cc.9.6.10994. · DOI
- Anisimov VN. Metformin for aging and cancer prevention. Aging (Albany NY) 2010; 2:760-74; PMID:21084729.
- Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG. Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer 2008; 8:501-5; PMID:19073504; DOI:10.3816/CBC.2008.n.060. · DOI
- Vázquez-Martin A, Oliveras-Ferraros C, del Barco S, Martin-Castillo B, Menendez JA. mTOR inhibi- tors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb). Clin Transl Oncol 2009; 11:455-9; PMID:19574203; DOI:10.1007/s12094-009-0384-0. · DOI
- Xia W, Husain I, Liu L, Bacus S, Saini S, Spohn J, et al. Lapatinib Antitumor Activity Is Not Dependent upon Phosphatase and Tensin Homologue Deleted on Chromosome 10 in ErbB2-Overexpressing Breast Cancers. Cancer Res 2007; 67:1170-5; PMID:17283152; DOI:10.1158/0008-5472.CAN- 06-2101. · DOI
- Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider. Diabetes Care 2006; 29:1990-1; PMID:16873829; DOI:10.2337/ dc06-0997. · DOI
- Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 2010; 9:1092- 9; PMID:20442309; DOI:10.1158/1535-7163.MCT- 09-1186. · DOI
- Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, et al. Metformin: taking away the candy for cancer? Eur J Cancer 2010; 46:2369-80; PMID:20656475; DOI:10.1016/j.ejca.2010.06.012. · DOI
- Hynes NE, Gullick W. Therapeutic targeting of signal transduction pathways and proteins in breast cancer. J Mammary Gland Biol Neoplasia 2006; 11:1-2; PMID:16865535; DOI:10.1007/s10911-006-9007-3. · DOI
- Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124:471-84; PMID:16469695; DOI:10.1016/j.cell.2006.01.016. · DOI · Paper page
- Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009; 8:909-15; PMID:19221498; DOI:10.4161/cc.8.6.7933. · DOI · Paper page
- Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009; 8:2031-40; PMID:19440038; DOI:10.4161/cc.8.13.8814. · DOI · Paper page
- Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, et al. Effect of metfromin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 2005; 40:685-93; PMID:16125352; DOI:10.1016/j.exger.2005.07.007. · DOI · Paper page
- Gonzalez-Angulo AM, Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 2010; 16:1695-700; PMID:20215559; DOI:10.1158/1078-0432.CCR-09-1805. · DOI
- Goodwin PJ, Ligibel JA, Stambolic V. Metformin in Breast Cancer: Time for Action. J Clin Oncol 2009; 27:3271-3; PMID:19487373; DOI:10.1200/ JCO.2009.22.1630. · DOI
- Vazquez-Martin A, Oliveras-Ferraros C, del Barco S, Martin-Castillo B, Menendez JA. The antidiabetic drug metformin: a pharmaceutical AMPK activator to over- come breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy. Ann Oncol 2009; 20:592-5; PMID:19153119; DOI:10.1093/annonc/ mdn758. · DOI
- Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, et al. Heterotrimerization of the growth factor receptors erbB2, erbB3 and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res 2010; 70:1204-14; PMID:20103628; DOI:10.1158/0008-5472.CAN-09-3321. · DOI
Cited by
Sorted by citations
Metformin as a tool to target aging
Barzilai, N., Crandall, J. P., Kritchevsky, S. B., & Espeland, M. A. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.011 · Cited by 1,096
Campbell, J. M., Bellman, S. M., Stephenson, M. D., & Lisy., K. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.08.003 · Cited by 455
Justice, J. N., Ferrucci, L., Newman, A. B., Aroda, V. R., Bahnson, J. L., Divers, J., Espeland, M. A., Marcovina, S., Pollak, M. N., Kritchevsky, S. B., et al. (2018) · GeroScience · doi:10.1007/s11357-018-0042-y · Cited by 359
Aging and Caloric Restriction Research: A Biological Perspective with Translational Potential
Balasubramanian, P., Howell, P. R., & Anderson, R. M. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.06.015 · Cited by 148
Quinn, B. J., Dallos, M., Kitagawa, H., Kunnumakkara, A. B., Memmott, R. M., Hollander, M. C., Gills, J. J., & Dennis, P. A. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0058-t · Cited by 85
Metadata
- Authors
- Liu, B., Fan, Z., Edgerton, S. M., Yang, X., Lind, S. E., & Thor, A. D.
- Venue
- Cell Cycle
- Publisher
- Informa UK Limited
- Published
- 2011-09
- Volume
- 10
- Issue
- 17
- Pages
- 2959-2966
- ISSN
- 1538-4101
- 1551-4005
- Cited by
- 120
- References
- 12
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
